•
Trastuzumab/pertuzumab :
L’essai Aphinity randomise chimiothérapie + trastuzumab à l’association chimiothérapie +
trastuzumab + pertuzumab
Au total, les études publiées ont mis en évidence un gain en faveur du double blocage tant en
situation néoadjuvante qu’en situation métastatique, sans effet délétère majeur au niveau de la
cardiotoxicité. Nous ne savons cependant pas quelles sont les patientes qui nécessitent ce
double blocage. Nous attendons les résultats des études adjuvantes
.
1.
Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, et al.
Overall survival benefit with lapatinib in combination with trastuzumab for patients with
human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from
the EGF104900 Study. J Clin Oncol. 2012 Jul 20;30(21):2585-92.
2.
Swain S, Clark E, Baselga J. Treatment of HER2-positive metastatic brast cancer. N
Engl J Med. 2015;372(20):1964-65.
3.
de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF,
et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO):
survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association
with pathological complete response. Lancet Oncol. 2014 Sep;15(10):1137-46.
4.
Robidoux A, Tang G, Rastogi P, Geyer CEJ, Azar CA, Atkins JN, et al. Lapatinib as a
component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP
protocol B-41): an open-label, randomised phase 3 tria. Lancet Oncol. 2013;14(12):1183-92.
5.
Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S, et al. Preoperative
chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor
2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J
Clin Oncol. 2012 Jun 1;30(16):1989-95.
6.
Holmes FA, Espina V, Liotta LA, Nagarwala YM, Danso M, McIntyre KJ, et al.
Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations
in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling. BMC Res Notes.
2013;6:507.
7.
Bonnefoi H, Jacot W, Saghatchian M, Moldovan C, Venat-Bouvet L, Zaman K, et al.
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an
anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised
phase II EORTC 10054 study. Ann Oncol. 2015 Feb;26(2):325-32.
8.
Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and
safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced,
inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre,
open-label, phase 2 trial. Lancet Oncol. 2012 Jan;13(1):25-32.
9.
Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus
trastuzumab in combination with standard neoadjuvant anthracycline-containing and
anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer:
a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013
Sep;24(9):2278-84.
10.
Bria E, Carbognin L, Furlanetto J, Pilotto S, Bonomi M, Guarneri V, et al. Impact of
neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological
